AbbVie Inc. stock holds Moderate Buy rating as shares trade near 52-week high
Published on 09/14/2026 at 16:29 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
AbbVie Inc. stock (ISIN US00287Y1091) is trading at USD 257.17 on the NYSE as of September 11, 2026, placing the pharmaceutical group’s shares within roughly USD 10 of their 52-week high and underlining continued investor confidence in the company’s earnings and pipeline.
Analysts maintain Moderate Buy stance
According to MarketBeat on September 14, 2026, AbbVie currently carries a consensus rating of Moderate Buy, with two analysts on Strong Buy, nineteen on Buy and five on Hold, and an average price target of USD 276.64, implying upside of about 7.6 percent from the recent NYSE level of USD 257.17.
The same overview from MarketBeat highlights a 52-week low of USD 190.75 and a 52-week high of USD 267.47 for AbbVie shares, so the current level is roughly 35 percent above the yearly low and about 3.9 percent below the high, a range that underscores how strongly the stock has recovered over the past year.
Recent price performance and market metrics
Per a price snapshot referenced in an article dated September 14, 2026, AbbVie opened at USD 257.17 on the first trading session of the week on the NYSE, matching the closing price from September 11, 2026, and marking a 0.8 percent gain versus the prior close as reported by a corporate-news overview on that date.
Based on the USD 257.17 share price and the company’s large-cap profile, AbbVie’s market capitalization stands in the tens of billions of USD, and the distance between the current level and the average analyst price objective of USD 276.64 indicates that, even near its 52-week high, the stock is still priced below the consensus target.
Investor positioning and rating context
Several institutional-investor filings summarized by MarketBeat on September 14, 2026, show portfolio adjustments but do not alter the broader view that AbbVie remains an attractive dividend and growth name in the biopharmaceutical sector, with the Moderate Buy consensus reflecting both the strength of its immunology franchises and the need to manage patent-expiry and competition risks.
The same day, an overview on MarketBeat reiterated that the average analyst price target of USD 276.64 for AbbVie stock compares with the recent USD 257.17 level on the NYSE, suggesting that, in the view of covering houses, there is still room for the shares to move higher if the company continues to deliver on earnings and cash flow.
Stock near high as of latest close
At the close on September 11, 2026, AbbVie Inc. stock finished at USD 257.17 on the NYSE, representing a 0.8 percent gain on the day and leaving the shares just USD 10.30 below the 52-week high of USD 267.47, while standing USD 66.42 above the 52-week low of USD 190.75, a positioning that many investors interpret as a sign of sustained confidence but also a reminder to watch upcoming earnings dates and guidance closely.
AbbVie Inc. stock master data
- Company: AbbVie Inc.
- ISIN: US00287Y1091
- Ticker: ABBV
- Trading venue: NYSE
- Price (as of September 11, 2026): 257.17 USD
- Market capitalization: [value] USD (as of September 11, 2026)
- Sector / Industry: Pharmaceuticals / Biotechnology
- Index membership: S&P 500
